All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
FDA grants regenerative medicine advanced therapy and fast-track designation to equecabtagene autoleucel for RRMM
On February 12, 2023, it was announced that equecabtagene autoleucel (previously known as CT103A), a BCMA-directed CAR T-cell therapy received both regenerative medicine advanced therapy and fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) multiple myeloma (MM). This follows the orphan drug designation in February 2022 and investigational new drug approval by the U.S FDA in December 2022.1
The Multiple Myeloma Hub previously reported the phase I clinical data of equecabtagene autoleucel in patients with RRMM which demonstrated increased persistency and efficacious responses, including those treated with prior murine BCMA CAR T-cell treatment. The updated phase Ib/II study results of the ongoing FUMANBA-1 trial (NCT05066646) were presented by Li2 during the European Hematology Association (EHA) 2022 Congress. Key results at the data cut off for the 79 evaluable patients with RRMM who were previously treated with at least three lines of therapy were as follows:
- An overall response rate of 94.9%, with 68.4% achieving a complete response rate or higher.
- A median time to response of 16 days.
- Observed responses in patients treated with prior non-BCMA CAR T-cell therapy.
- MRD-negativity in 92.4% overall.
- All cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome incidences were Grade 1 and 2 and none were Grade 3 or higher.
- Equecabtagene autoleucel demonstrated prolonged persistency and low immunogenicity.
Additional ongoing clinical trials with equecabtagene autoleucel are:
- A phase I study combined with selinexor in patients with extramedullary RRMM and had at least three prior lines of therapy (NCT05201118).
- A phase I study in patients with high-risk newly diagnosed MM (FUMANBA-2, NCT05181501), defined as Revised International Staging System (R-ISS) Stage 3, double-hit, or triple-hit.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?